Dennis Vanderheiden of Fort Collins, Colorado, is propelling two people forward as he cycles 585 miles in 13 days across his home state to raise money for Angelman syndrome research. A buddy with the disorder, Paul James (P.J.) Snyder, is riding in the bike trailer that Vanderheiden pulls across Colorado’s…
ANAVEX 2-73 significantly reduced sound-triggered seizures in mice with Angelman syndrome, according to a preclinical-trial study. Its developer, Anavex Life Sciences, reported the results at the Antiepileptic Drug Trials XIV 2017 Conference  in North Miami Beach, May 17-19. The presentation was titled “ANAVEX 2-73,…
Ovid Therapeutics is conducting two clinical trials assessing its lead candidate OV101 for the treatment of adolescents and adults with Angelman syndrome. Both trials are currently enrolling participants. “Ovid has a clear strategy and business plan to build a neurology company focused on rare disorders of the brain,” Jeremy…
Get regular updates to your inbox.